Stock Ratings / Health Care / ICUI / earnings

IRTC (48) PLSE (41) NVST (49) HTFL (53) ⌘ Pro Terminal →

ICU Medical Inc. (ICUI) Next Earnings Date & Expected ±6.5% Move

$168.65 +1.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $168.74

ICU Medical Inc. (ICUI) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $4.22B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ICUI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ICUI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, ICU Medical Inc. (NASDAQ: ICUI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $168.65 (+1.36% 1D, market cap $4.22B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, ICUI ranks #278 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ICUI compare to IRTC and PLSE in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), ICUI carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of 36.8%, and ROIC of 1.0%. By comparison, IRTC (iRhythm Holdings Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -13.5%, cap $4.21B) and PLSE (Pulse Biosciences Inc) posts a D- grade (41/100 RQD, P/E N/A, ROIC -30.7%, cap $3.96B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ICUI?

▼

Per ICUI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000883984), ICU Medical Inc. generated $2.23B in revenue (-6.3% YoY), $732.0K in net income, and $91.8M in free cash flow against $4.05B in total assets and $1.27B in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $168.73 (+0.05%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 4.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE-1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICUI)Realized 20D OHLCV Swing Band: ±6.5%

Deterministic 5-Pillar Attribution (55/100 Composite)

🔍 WHY ICUI SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (22% of score)

FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 50.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$160.32+1.7% Next Q

Q2 (-2Q)

Grade C-$162.99+2.2% Next Q

Q3 (-1Q)

Grade C-$166.62+1.2% Next Q

Current

Grade D+$168.65-0.5% Hist 90D α

Trajectory: D (47) → D+ (55)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ICUI Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, ICUI faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.68% YoY Shares) — any gross margin slip below 34.3% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($164.22) or 200D SMA ($148.59) invalidates the momentum regime and cuts Target Base ($166.37) toward Bear Floor ($129.77).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICUI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ICUI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 55%NO 45%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±6.5% Swing Band

±$10.96 Expected Swing

MODEL EARNINGS SETUP GAUGE

ICUI Quantitative Pre-Earnings Setup: 55/100

Trailing EPS: $4.25 • YoY Revenue Growth: -6.3%

Model Bullish Setup (55/100)Model Risk Weight (45/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$2.23B	$732.0K	$91.8M	36.8%
FY 2024	2024-12-31	$2.38B	-$117.7M	$124.7M	34.6%
FY 2023	2023-12-31	$2.26B	-$29.7M	$166.2M	36.8%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ICUI)

✓Walkthrough of ICUI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ICUI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +41.48%▲ ASCENDING CHANNEL

2026-10-30O $169.6H $170.0L $163.2C $168.7VOL 216.6K

RES: $225.8SUP: $158.1SMA50: $164.2SMA200: $148.6

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICUI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ICUI Butterfly Map → + Track ICUI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

40.6%/yr Implied 5Y Growth

vs. -6.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ICUI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ICUI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ICUI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICUI)

Health Care Rank #278 of 1016 ⚔️ IRTC vs ICUI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ICUI vs. IRTC, PLSE, NVST, HTFL)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ICU Medical Inc. (ICUI) ranks #278 by composite RQD confidence (55/100, grade D+) and #178 by equity capitalization ($4.22B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ICUI currently leads its immediate peer cohort in composite quantitative strength at 55/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ICUI ACTIVE ICU Medical Inc.	D+	55/100	—	36.8%	1.0%	+1.36%	$4.22B	Benchmark Subject
IRTC iRhythm Holdings Inc.	D	48/100	—	70.6%	-13.5%	+3.07%	$4.21B	/irtc-vs-icui →
PLSE Pulse Biosciences Inc	D-	41/100	—	-30.0%	-30.7%	+3.37%	$3.96B	/plse-vs-icui →
NVST Envista Holdings Corporation	D	49/100	84.1x	54.7%	5.1%	+2.80%	$3.95B	/nvst-vs-icui →
HTFL Heartflow Inc.	D+	53/100	—	76.8%	-12.0%	+2.42%	$5.26B	/htfl-vs-icui →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000883984

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ICU Medical Inc. (ICUI) reported GAAP revenue of $2.23B (-6.3% vs. FY2024 revenue of $2.38B , and -1.2% cumulative change since FY2023) , GAAP net income of $732.0K, operating cash flow of $179.8M, and free cash flow of $91.8M (-26.4% YoY). On the balance sheet, ICUI closed FY2025 with $4.05B in total assets against $1.27B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.23B	$732.0K	$179.8M	$91.8M	$4.05B	$1.27B
FY2024 (FY)	2024-12-31	$2.38B	-$117.7M	$204.0M	$124.7M	$4.20B	$1.53B
FY2023 (FY)	2023-12-31	$2.26B	-$29.7M	$166.2M	$166.2M	—	—

3. ICUI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICUI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ICUI compare to IRTC and PLSE in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ICUI?

Where is ICUI trading relative to its 50-day, 200-day, and 52-week technical levels?

ICUI last traded at $168.65 (+1.36% on volume of 202,523 shares), positioning the stock +2.70% above its 50-day simple moving average ($164.22) and +13.50% above its 200-day simple moving average ($148.59). Across its 52-week range of $113.37 to $192.85, ICUI sits at the 69.6% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($157.69 to $179.61).